Literature DB >> 2193616

Patterns and mechanisms of beta-lactam resistance among isolates of Escherichia coli from hospitals in the United States.

R Cooksey1, J Swenson, N Clark, E Gay, C Thornsberry.   

Abstract

To study the national distribution of beta-lactam resistance patterns and mechanisms among Escherichia coli organisms isolated in U.S. hospitals, 652 ampicillin-resistant (Am(r)) or ampicillin-intermediate (Ami) isolates were submitted to the Centers for Disease Control from March 1983 through July 1984 by nine hospitals participating in the National Nosocomial Infections Study. Among the isolates (most of which caused urinary tract infections), 78% were Am(r) and 22% were Ami by the interpretative criteria established by the National Committee for Clinical Laboratory Standards. Resistance to carboxypenicillins ranged from 73 to 74%, and that to acylureidopenicillins ranged from 43 to 66%. A total of 26% of the isolates were resistant to cephalothin, and 4% were resistant to cefazolin. Resistance to cefoxitin was 1%, while resistances to cefuroxime and cefamandole were 2 and 7%, respectively. With the exception of cefsulodin (98% resistant) and cefoperazone (1% resistant), there was no resistance to newer cephalosporins or aztreonam. In general, only minor differences in the incidence of resistance to beta-lactam antibiotics were noted in hospital-acquired versus non-hospital-acquired isolates as well as among isolates from various regions of the United States. TEM beta-lactamases were produced by 87% of the 237 Am(r) isolates examined. By our methods, OXA and chromosomal (type I) beta-lactamases were detected in 2 and 28 isolates, respectively, and plasmid-mediated extended-spectrum cephalosporinases were detected in none of the isolates. Disk substrate and clavulanic acid inhibition assays revealed that TEM beta-lactamase conferred Am(r) and resistance to carboxypenicillins, acylureidopenicillins, cephalothin, cefamandole, cefsulodin, and cefoperazone. A total of 391 isolates were screened for plasmids, and 259 isolates were examined by DNA hybridization with a TEM probe. Among 462 plasmids probed, 129 plasmids, ranging from 4 to 140 megadaltons, harbored TEM sequences. Although beta-lactam resistance in clinical isolates of E. coli is predominantly mediated by TEM beta-lactamase, the diverse spectrum of resistance appears to be related to additional strain=dependent factors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193616      PMCID: PMC171683          DOI: 10.1128/AAC.34.5.739

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Detection of beta-lactamase production by gram-negative bacteria.

Authors:  G Masuda; S Tomioka; M Hasegawa
Journal:  J Antibiot (Tokyo)       Date:  1976-06       Impact factor: 2.649

2.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

Review 3.  Plasmid-mediated beta-lactamases of Gram-negative bacteria: properties and distribution.

Authors:  M Matthew
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

4.  Frequency of plasmid-determined beta-lactamases in 680 consecutively isolated strains of Enterobacteriaceae.

Authors:  C Roy; C Segura; M Tirado; R Reig; M Hermida; D Teruel; A Foz
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

5.  A gene probe for TEM type beta-lactamases.

Authors:  R C Cooksey; N C Clark; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

6.  Evolution of plasmid-coded resistance to broad-spectrum cephalosporins.

Authors:  C Kliebe; B A Nies; J F Meyer; R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Resistance to beta-lactams in Enterobacteriaceae: distribution of phenotypes related to beta-lactamase production.

Authors:  D Sirot; J Sirot; P Saulnier; B Joly; M Chanal; M Cluzel; R Cluzel
Journal:  J Int Med Res       Date:  1986       Impact factor: 1.671

8.  Beta-lactam resistance in clinical isolates of Escherichia coli caused by elevated production of the ampC-mediated chromosomal beta-lactamase.

Authors:  S Bergström; S Normark
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

9.  beta-Lactamases and beta-lactam resistance in Escherichia coli.

Authors:  G A Jacoby; L Sutton
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

10.  Effects of beta-lactamases and omp mutation on susceptibility to beta-lactam antibiotics in Escherichia coli.

Authors:  M Hiraoka; R Okamoto; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  20 in total

1.  Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles.

Authors:  L Martínez-Martínez; M C Conejo; A Pascual; S Hernández-Allés; S Ballesta; E Ramírez De Arellano-Ramos; V J Benedí; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Identification of amino acid substitutions that alter the substrate specificity of TEM-1 beta-lactamase.

Authors:  T Palzkill; D Botstein
Journal:  J Bacteriol       Date:  1992-08       Impact factor: 3.490

3.  Problems in interpretation of piperacillin susceptibility of TEM-1 producing Escherichia coli in the disk diffusion test.

Authors:  T Arstila; S Huovinen; P Huovinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

4.  Properties of plasmids responsible for production of extended-spectrum beta-lactamases.

Authors:  G A Jacoby; L Sutton
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

5.  Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.

Authors:  D Vanjak; C Muller-Serieys; B Picard; E Bergogne-Berezin; N Lambert-Zechovsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

6.  Systematic mutagenesis of the active site omega loop of TEM-1 beta-lactamase.

Authors:  J F Petrosino; T Palzkill
Journal:  J Bacteriol       Date:  1996-04       Impact factor: 3.490

Review 7.  Genetics of extended-spectrum beta-lactamases.

Authors:  G A Jacoby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

8.  Carriage of antibiotic-resistant Escherichia coli by healthy volunteers during a 15-week period.

Authors:  N London; R Nijsten; A van der Bogaard; E Stobberingh
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

9.  Piperacillin/tazobactam in complicated urinary tract infections.

Authors:  P Nowé
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

10.  Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli.

Authors:  E C Nelson; B G Elisha
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.